InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,713.64
(
1.70%
)
US TECH 100
19,296.40
(
-0.20%
)
Dow Jones
42,025.19
(
1.26%
)
Brent Oil
74.15
(
-0.24%
)
Bitcoin
63,434.78
(
0.77%
)
Post# of 10809
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Bobwins

Send PM Follow Ignore
Followers 556
Posts 17440
Boards Moderated 42
Alias Born 10/21/2003

Bobwins

Re: Bobwins post# 10446

Tuesday, 07/03/2018 10:50:25 AM

Tuesday, July 03, 2018 10:50:25 AM

Post# of 10809
ATE.v/ATBPF +.01 to C$.39

https://finance.yahoo.com/news/antibe-therapeutics-releases-secondary-endpoint-110000421.html

These are the details of the phase II study that was announced earlier by Antibe. Very low levels of ulceration vs standard naproxen(ALEVE). Nothing unexpected and everything points towards what should be a successful phase III but you can never be sure with drug candidates.

Antibe has cash to complete their scheduled phase IIC trial for optimal dosage this winter. Should be completed by early 2019.

Still hunting for a big Daddy partner to fund phase III. Company estimated it could take up to a year to find the right partner.

Please post stock symbols first in all your posts. If it's a foreign stock, please list the US pk equivalent symbol.

If the Commodities Boom is Over, I am just a Gold Bug headed for the Windshield of LIFE

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up